Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/07/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 100 publications

Reversible Left Ventricular Dysfunction Related to Ropeginterferon Alfa-2b in Polycythemia Vera.

Reversible Left Ventricular Dysfunction Related to Ropeginterferon Alfa-2b in Polycythemia Vera.

Journal: International heart journal
Published: November 30, 2025

Ropeginterferon alfa-2b in Polycythemia Vera: redefining disease control through molecular targeting.

Ropeginterferon alfa-2b in Polycythemia Vera: redefining disease control through molecular targeting.

Journal: Expert review of anticancer therapy
Published: November 19, 2025

Effective Treatment with Ruxolitinib and Ropeginterferon Alfa-2b for Refractory TAFRO-like Syndrome.

Effective Treatment with Ruxolitinib and Ropeginterferon Alfa-2b for Refractory TAFRO-like Syndrome.

Journal: Internal medicine (Tokyo, Japan)
Published: October 29, 2025

Pharmacologic management of ET: established therapies and emerging agents.

Pharmacologic management of ET: established therapies and emerging agents.

Journal: Expert opinion on pharmacotherapy
Published: October 27, 2025

The combination of ropeginterferon alfa-2b with anti-PD1 blockage in adjuvant therapy in HBV-related HCC.

The combination of ropeginterferon alfa-2b with anti-PD1 blockage in adjuvant therapy in HBV-related HCC.

Journal: Hepatology international
Published: October 05, 2025

Towards New Therapy Endpoints in Polycythemia Vera: Targeting Clonal and Inflammatory Pathways.

Towards New Therapy Endpoints in Polycythemia Vera: Targeting Clonal and Inflammatory Pathways.

Journal: Blood advances
Published: August 28, 2025

A new era in the treatment of myeloproliferative neoplasms

A new era in the treatment of myeloproliferative neoplasms

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: August 06, 2025

A comparative study of hematologic response to ropeginterferon alfa-2b in hydroxyurea-resistant or intolerant polycythemia vera: a real-world data-based analysis.

A comparative study of hematologic response to ropeginterferon alfa-2b in hydroxyurea-resistant or intolerant polycythemia vera: a real-world data-based analysis.

Journal: Blood research
Published: August 03, 2025

Long-term Efficacy and Safety of Ropeginterferon Alfa-2b under its HIDAT Regimen for the Treatment of Polycythemia Vera.

Long-term Efficacy and Safety of Ropeginterferon Alfa-2b under its HIDAT Regimen for the Treatment of Polycythemia Vera.

Journal: Blood advances
Published: August 01, 2025

Ropeginterferon alfa-2b vs standard therapy in polycythemia vera: A meta-analysis of efficacy and safety outcomes.

Ropeginterferon alfa-2b vs standard therapy in polycythemia vera: A meta-analysis of efficacy and safety outcomes.

Journal: World journal of clinical oncology
Published: July 28, 2025

Efficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis.

Efficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis.

Journal: Annals of hematology
Published: July 22, 2025

Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.

Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.

Journal: The Lancet. Haematology
Published: June 11, 2025
Showing 1-12 of 100

Last Updated: 01/07/2026